First clinical experience with Zr-89-Df-IAB22M2C PET/MRI in patients with metastatic cancer

被引：0
|
作者：
Schwenck, J. [1 ,2 ,3 ]
Sonanini, D. [2 ,4 ]
Seyfried, D. [2 ]
Ehrlichmann, W. [2 ]
Kienzle, G. [2 ]
Reischl, G. [2 ,3 ]
Wilson, I. [5 ]
Le, W. [5 ]
Smith, G. [5 ]
Korn, R. [5 ]
Seith, F. [6 ]
Forschner, A. [7 ]
Eigentler, T. [7 ]
Roecken, M. [3 ,7 ,8 ]
Zender, L. [3 ,4 ,8 ]
Pichler, B. [2 ,3 ,8 ]
Flatz, L. [7 ]
Kneilling, M. [2 ,3 ,7 ]
la Fougere, C. [1 ,3 ,8 ]
机构：
[1] Eberhard Karls Univ Tubingen, Dept Nucl Med & Clin Mol Imaging, Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Dept Preclin Imaging & Radiopharm, Werner Siemens Imaging Ctr, Tubingen, Germany
[3] Eberhard Karls Univ Tubingen, Cluster Excellence iFIT EXC 2180 Image Guided & F, Tubingen, Germany
[4] Eberhard Karls Univ Tubingen, Dept Med Oncol & Pneumol Internal Med 8, Tubingen, Germany
[5] ImaginAb Inc, Inglewood, CA USA
[6] Eberhard Karls Univ Tubingen, Dept Diagnost & Intervent Radiol, Tubingen, Germany
[7] Eberhard Karls Univ Tubingen, Dept Dermatol, Tubingen, Germany
[8] German Canc Res Ctr DKFZ Partner Site Tubingen, German Canc Consortium DKTK, Tubingen, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0863
引用
收藏
页码：S303 / S304
页数：2
相关论文
共 50 条
  • [21] Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as a Potential Imaging Biomarker in Targeted Immuno-Therapeutic Drug Development of a GUCY2C-CD3 bispecific antibody PF-07062119.
    Maresca, Kevin
    Chen, Jianqing
    Mathur, Divya
    Giddabasappa, Anand
    Root, Adam
    Narula, Jatin
    King, Lindsay
    Schaer, David
    Golas, Jonathan
    Rosfjord, Edward
    Ram, Sripad
    Pickering, Eve
    Hardwick, James
    Rejto, Paul
    Ilovich, Ohad
    Staton, Kevin
    Wilson, Ian
    McCarthy, Timothy
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [22] HER-2-PET imaging with 89Zr-trastuzumab in metastatic breast cancer patients
    Munnink, T. Oude
    Dijkers, E.
    Hooge, M. Lub-de
    Kosterink, J.
    Brouwers, A.
    de Jong, J.
    van Dongen, G.
    de Vries, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Phase II, open label, multi-dose study of 89-Zr-Df-IAB22M2C (CD8 Immuno-PET Tracer): technical handling and injection instructions for optimal tracer administration
    Allred, Kaylee
    Sanders, Quinten
    Prince, Monica
    Korn, Ron
    Wilson, Ian
    Le, William
    Weiss, Avital
    Abbott, Amanda
    Hays, David
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [24] 89Zr-IAB2M minibody imaging in patients with prostate cancer: Biodistribution, kinetics, lesion uptake and organ dosimetry
    Pandit-Taskar, Neeta
    Joseph, O.
    Lyashchenko, Serge
    Carrasquillo, Jorge
    Keppler, Jennifer
    Wu, Anna
    Weber, Wolfgang
    Scher, Howard
    Larson, Steven
    Morris, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [25] Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA 89Zr-Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients
    Korn, Ronald
    Gburek, Benard
    Woodruff, Anthony
    Verma, Nishant
    Siebenkaess, Danielle
    Wyman, Bradley
    Wright, Cameron
    Masci, Peter
    Keppler, Jennifer
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [26] Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
    Matsuda, Masahide
    Ishikawa, Eiichi
    Yamamoto, Tetsuya
    Hatano, Kentaro
    Joraku, Akira
    Iizumi, Yuichi
    Masuda, Yosuke
    Nishiyama, Hiroyuki
    Matsumura, Akira
    JOURNAL OF NEURO-ONCOLOGY, 2018, 138 (03) : 581 - 589
  • [27] Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
    Masahide Matsuda
    Eiichi Ishikawa
    Tetsuya Yamamoto
    Kentaro Hatano
    Akira Joraku
    Yuichi Iizumi
    Yosuke Masuda
    Hiroyuki Nishiyama
    Akira Matsumura
    Journal of Neuro-Oncology, 2018, 138 : 581 - 589
  • [28] Clinical value of 89Zr-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma
    Schroder, C. P.
    Bensch, F.
    Brouwers, A. H.
    Lub-de Hooge, M. N.
    de Jong, J. R.
    van der Vegt, B.
    Sleijfer, S.
    de Vries, E. G.
    CANCER RESEARCH, 2017, 77
  • [29] Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
    Dijkers, E. C.
    Munnink, T. H. Oude
    Kosterink, J. G.
    Brouwers, A. H.
    Jager, P. L.
    de Jong, J. R.
    van Dongen, G. A.
    Schroder, C. P.
    Lub-de Hooge, M. N.
    de Vries, E. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 586 - 592
  • [30] CD8 PET IMAGING OF TUMOR INFILTRATING T CELLS IN ADVANCED SOLID TUMORS: A PHASE I FIRST-INHUMAN STUDY OF 89ZR-IAB22M2C, A RADIOLABELED ANTI-CD8 MINIBODY
    Farwell, Michael
    Gamache, Raymond
    Pandit-Taskar, Neeta
    Postow, Mike
    Gordon, Michael
    Wilson, Ian
    Mascioni, Alessandro
    Wu, Anna
    Le, William
    Weiss, Avital
    Korn, Ronald
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A179 - A180
12345